within Pharmacolibrary.Drugs.ATC.C;

model C08DB01_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0011083333333333333,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.305,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.119,
    k12             = 34.4,
    k21             = 34.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C08DB01_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Diltiazem is a non-dihydropyridine calcium channel blocker (class IV antiarrhythmic) used to treat hypertension, angina pectoris, and arrhythmias. It is clinically approved and in use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after intravenous administration in healthy adults.</p><h4>References</h4><ol><li><p>Hermann, P, et al., &amp; Morselli, PL (1983). Pharmacokinetics of diltiazem after intravenous and oral administration. <i>European journal of clinical pharmacology</i> 24(3) 349–352. DOI:<a href=&quot;https://doi.org/10.1007/BF00610053&quot;>10.1007/BF00610053</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6861848/&quot;>https://pubmed.ncbi.nlm.nih.gov/6861848</a></p></li><li><p>Dias, VC, et al., &amp; Ellenbogen, KA (1992). Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. <i>Circulation</i> 86(5) 1421–1428. DOI:<a href=&quot;https://doi.org/10.1161/01.cir.86.5.1421&quot;>10.1161/01.cir.86.5.1421</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1423955/&quot;>https://pubmed.ncbi.nlm.nih.gov/1423955</a></p></li><li><p>Schwarzwald, CC, et al., &amp; Bonagura, JD (2006). Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. <i>Journal of veterinary pharmacology and therapeutics</i> 29(3) 165–171. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2885.2006.00733.x&quot;>10.1111/j.1365-2885.2006.00733.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16669860/&quot;>https://pubmed.ncbi.nlm.nih.gov/16669860</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C08DB01_1;
